欧洲-美国淋病奈瑟菌抗菌药物敏感性试验外部质量评估方案–2024

October 2025 ECDCSURVEILLANCE AND MONITORING Euro-GASP external quality assessmentscheme forN eisseria gonorrhoeaeantimicrobial susceptibility testing – 2024 October 2025 This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated byCsaba Ködmön and produced by Melissa Jansen van Rensburg, Sarah Alexander and Michelle Cole, UK HealthSecurity Agency, London, and Susanne Jacobsson, Daniel Schröder and Magnus Unemo, Örebro University Hospital,on behalf of the EURO-GASP network participants. Suggested citation: European Centre for Disease Prevention and Control. Euro-GASP external quality assessmentscheme forNeisseria gonorrhoeae antimicrobial susceptibility testing – 2024. Stockholm: ECDC; 2025. Stockholm, October 2025 ISBN 978-92-9498-827-0doi: 10.2900/4051811Catalogue number TQ-01-25-057-EN-N Contents Abbreviations ............................................................................................................................................... ivExecutive summary ........................................................................................................................................11. Introduction ..............................................................................................................................................22. Materials and methods ...............................................................................................................................32.1 Antimicrobial susceptibility testing external quality assessment panel .......................................................32.2 Antimicrobial susceptibility testing methods ...........................................................................................32.3 Analysis and interpretation of the results...............................................................................................43. Results......................................................................................................................................................53.1 2024 EQA panel strain characteristics....................................................................................................53.2 EQA participation ................................................................................................................................53.3 Antimicrobial susceptibility testing methods ...........................................................................................83.4 Interpretation of MICs .........................................................................................................................83.5 Modifications to EQA scoring for atypical results.....................................................................................83.6 Coded breakdown of completeness and concordance .............................................................................93.7 Susceptibility category concordance ....................................................................................................103.8 MIC concordance ..............................................................................................................................113.9 Intra-laboratory concordance .............................................................................................................143.10 Overall EQA scores ..........................................................................................................................154. Discussion ...............................................................................................................................................175. Conclusion...............................................................................................................................................18References ..................................................................................................................................................19Annex. QA24 detailed results ........................................................................................................................21 Figures Figure 1. Countries participating in the 2024N. gonorrhoeae susceptibility testing EQA scheme............................5Figure 2. Longitudinal comparison of EQA interlaboratory antimicrobial categorical agreement, EU/EEA, 2007-2024 . 11Figure 3. Longitudinal comparison of EQA interlaboratory MIC concordance, percentage of essential agreement (greenline) and percentage of results within two doubling dilutions of the modal MIC (black line), EU/EEA, 2010-2024 ...... 13Figure 4. Intra-laboratory MIC concordance percentage 2023 vs 2024 ..............................................................14Figure 5. EQA overall MIC scores, 2023 vs 2024 .............................................................................................15Figure 6. EQA overall categorical agreement scores, 2024 ........................................................